Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Lamivudine

SKU: orb1226481

Description

Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor with an IC50 of 2.7 mM.(In Vitro):Lamivudine (1 μM) is potent inhibitor of hepatitis B virus (HBV) replication, shows antiviral activity in primary duck hepatocyte (PDH) cultures derived from ducklings congenitally infected with the duck hepatitis B virus (DHBV).Lamivudine (0-20 μM; 2, 4, 9 d) inhibits DHBV replication with 50% inhibitory concentration of 0.55 μM.Lamivudine, combinded with penciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine [PCV]), (1 μM; 2, 4, 9 d) shows synergistic effect, acts potent function in reducing the normally recalcitrant viral covalently closed circular (CCC) DNA form of DHBV.(In Vivo):Lamivudine (20-500 mg/kg/d; p.o.; 15 or 45 d) causes oxidative stress and is toxic to rat liver.Lamivudine (50 mg/kg; i.p.; single dose) penetrates well in CNS and localizes in brain regions susceptible to HIV neurodegeneration in rat.

Research Area

Pharmacology & Drug Discovery

Images & Validation

Key Properties

CAS Number134678-17-4
MW229.26
Purity>98% (HPLC)
FormulaC8H11N3O3S
SMILESO=C1N=C(N)C=CN1[C@@H]2CS[C@H](CO)O2
TargetReverse Transcriptase
SolubilityWater: 46 mg/mL (200.64 mM); DMSO: 46 mg/mL (200.64 mM)

Bioactivity

In Vivo
Lamivudine (20-500 mg/kg/d; p.o. ; 15 or 45 d) causes oxidative stress and is toxic to rat liver. Lamivudine (50 mg/kg; i.p.; single dose) penetrates well in CNS and localizes in brain regions susceptible to HIV neurodegeneration in rat.
In Vitro
Lamivudine (1 μM) is potent inhibitor of hepatitis B virus (HBV) replication, shows antiviral activity in primary duck hepatocyte (PDH) cultures derived from ducklings congenitally infected with the duck hepatitis B virus (DHBV). Lamivudine (0-20 μM; 2, 4, 9 d) inhibits DHBV replication with 50% inhibitory concentration of 0.55 μM. Lamivudine, combinded with penciclovir (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine [PCV]), (1 μM; 2, 4, 9 d) shows synergistic effect, acts potent function in reducing the normally recalcitrant viral covalently closed circular (CCC) DNA form of DHBV.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

(-)-BCH 189 | Epivir | Epivir-HBV | 3TC

Similar Products

  • 3TCTP [orb63437]

    ≥ 95% (HPLC)

    143188-53-8

    Theoretical MW: 469.19 g/mol (free acid); Detected MW: 468.95 g/mol (free acid)

    C8H14N3O12P3S

    5 x 5 μl
  • 3TCMP [orb63438]

    ≥ 95% (HPLC)

    Theoretical MW: 309.23 g/mol (free acid); Detected MW: 309.02 g/mol (free acid)

    C8H12N3O6PS

    5 x 10 μl
  • Lamivudine salicylate [orb1688608]

    173522-96-8

    367.38

    C15H17N3O6S

    50 mg, 25 mg, 100 mg
  • TLR8 agonist 4 [orb1686189]

    545.61

    C28H27N5O5S

    50 mg, 100 mg, 25 mg
  • Lamivudine sulfoxide, (R)- [orb1705545]

    160552-54-5

    245.26

    C8H11N3O4S

    25 mg, 50 mg, 100 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Protocol Information

Available Sizes

Select a size below

50 mg
$ 100.00
100 mg
$ 140.00
500 mg
$ 310.00